Synthetic lethal analyses have reported that MTAP−/− cancers are unusually susceptible to agents targeting MAT2A, RIOK1 or PRMT5, thus MAT2A and PRMT5 have been implicated as anti-cancer targets in MTAP−/− cancer cell lines18–20. The gene discussed is MAT2A; the disease is cancer.